Duloxetine
Product Images NDC 50436-0747

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50436-0747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of the active ingredient in Duloxetine Delayed-Release, showing its molecular framework including thiophene and naphthalene rings with associated functional groups.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line chart showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: placebo (dashed line) and Duloxetine delayed-release capsules (solid line), indicating that patients taking Duloxetine have a lower proportion of relapse over the observed period of up to 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time in days after randomization. It compares relapse rates between placebo and duloxetine delayed-release capsules, with placebo showing a higher proportion of relapse over time.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline for Duloxetine Delayed-Release at doses of 60mg twice daily, 60mg once daily, and 20mg once daily, compared to placebo. The graph shows downward trends in the percentage of patients improved as the percent improvement threshold increases, with data points and legend identifying each treatment group.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Both Duloxetine groups show higher improvement rates than the placebo across all measured percent improvements.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine Delayed-Release 60mg twice daily, 60mg once daily, and placebo. The vertical axis represents percentage of patients improved, and the horizontal axis shows percent improvement in pain.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine Delayed-Release 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The x-axis shows percent improvement in pain, while the y-axis displays the percentage of patients improved. The plot tracks the trends of these variables across the different dosage groups and placebo.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between a placebo group and Duloxetine Delayed-Release 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Two curves show treatment efficacy over varying improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line chart comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine Delayed-Release 60 mg once daily. The chart shows two lines, with Duloxetine generally showing higher percentages of patient improvement across pain improvement percentages from >0 to 100%.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily and placebo. The graph shows two lines, one marked with filled diamonds for Duloxetine and one with crosses for placebo, illustrating greater patient improvement with Duloxetine across increasing pain improvement percentages.*

FDA Label Image

Label Image (Lbl504360747)

Label for Duloxetine Hydrochloride Delayed-Release 30 mg capsules, 30 capsules per package, distributed by Breckenridge Pharm, Inc. in Berlin, CT. Each capsule contains 33.7 mg of duloxetine hydrochloride USP equivalent to 30 mg duloxetine. Includes storage instructions, warnings, NDC 50436-0747-01, lot and expiration date placeholders, and states prescription use only. Packaged by Unit Dose Services in Dallas, FL.*

FDA Label Image

Label Image (Lbl504360748)

Duloxetine Delayed-Release 60 mg capsules, 30 count, from Unit Dose Services. The label shows the active ingredient amount as 67.3 mg duloxetine hydrochloride USP equivalent to 60 mg duloxetine. The product is distributed by Breckenridge Pharm, Inc., Berlin, CT. The label includes storage instructions to keep out of reach of children and store at controlled room temperature 25°C (77°F). It is Rx only and comes with a specific NDC code 50436-0748-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.